Abiopharma

🔍 Schwaneke Jeffrey A. (Executive)

Company: agilon health, inc. (AGL)

Report Date: 2026-04-01

Detailed Transactions and Holdings:

• Sold 1,662 shares of Common Stock at $9.75 per share (Direct)
  Date: 2026-04-01 | Code: F | equity_swap_involved: 0 | shares_owned_after: 65,342.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Acquired 75,000 shares of Common Stock (Direct)
  Date: 2026-04-01 | Code: A | equity_swap_involved: 0 | shares_owned_after: 140,342.00 | transaction_form_type: 4 | Footnotes: F3, F4
• Holds 0 shares of Common Stock (Direct)
  Date: 2026-04-01 | Code: H | nature_of_ownership: By trust | shares_owned_after: 892.00 | Footnotes: F5

Footnotes:

• F1: Represents the number of shares of Common Stock that have been withheld by the issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of the restricted stock units and does not represent a sale.
• F2: The amount of securities beneficially owned following the reported transaction reflects the 1 for 25 reverse stock split of the Issuer's issued and outstanding common stock effective March 30, 2026.
• F3: Restricted stock units that vest in three equal installments on each anniversary of April 1, 2026, subject to continued employment.
• F4: Includes restricted stock units.
• F5: The amount of securities beneficially owned reflects the 1 for 25 reverse stock split of the Issuer's issued and outstanding common stock effective March 30, 2026.